These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37099141)

  • 1. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and the Risk of Fracture: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Lv F; Cai X; Lin C; Yang W; Hu S; Ji L
    Calcif Tissue Int; 2023 Aug; 113(2):175-185. PubMed ID: 37099141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression.
    Rivera FB; Cha SW; Magalong JV; Bantayan NRB; Cruz LLA; Arias-Aguirre E; Aguirre Z; Varona MC; Co EMF; Lumbang GNO; Enkhmaa B
    Curr Med Res Opin; 2024 Jul; 40(7):1103-1121. PubMed ID: 38836510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression.
    Hirsh Raccah B; Yanovsky A; Treves N; Rotshild V; Renoux C; Danenberg H; Eliaz R; Matok I
    Int J Cardiol; 2021 Jul; 335():7-14. PubMed ID: 33892045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Ezetimibe on Risk of New-Onset Diabetes: A Systematic Review and Meta-Analysis of Large, Double-Blinded Randomized Controlled Trials.
    Chiu SW; Pratt CM; Feinn R; Chatterjee S
    J Cardiovasc Pharmacol Ther; 2020 Sep; 25(5):409-417. PubMed ID: 32419478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias' treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network metaanalysis.
    Pamporis K; Karakasis P; Simantiris S; Sagris M; Bougioukas KI; Fragakis N; Tousoulis D
    Clin Investig Arterioscler; 2024; 36(2):86-100. PubMed ID: 38040529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Imbalzano E; Ilardi F; Orlando L; Pintaudi B; Savarese G; Rosano G
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):318-327. PubMed ID: 36972610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years.
    de Carvalho LSF; Campos AM; Sposito AC
    Diabetes Care; 2018 Feb; 41(2):364-367. PubMed ID: 29180351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between biologic therapy and fracture incidence in patients with selected rheumatic and autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
    Lv F; Hu S; Lin C; Cai X; Zhu X; Ji L
    Pharmacol Res; 2022 Jul; 181():106278. PubMed ID: 35644324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials.
    Benhuri B; Ueyama H; Takagi H; Briasoulis A; Kuno T
    Curr Vasc Pharmacol; 2021; 19(4):390-397. PubMed ID: 32767943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Chen Q; Wu G; Li C; Qin X; Liu R; Zhang M
    Am J Cardiovasc Drugs; 2020 Aug; 20(4):343-353. PubMed ID: 31823301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials.
    Geng Q; Li X; Sun Q; Wang Z
    Cardiol J; 2022; 29(4):574-581. PubMed ID: 34581425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
    Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
    Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies.
    Bagepally BS; Sasidharan A
    Eur J Clin Pharmacol; 2022 Mar; 78(3):351-363. PubMed ID: 34708270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis.
    Zhao Z; Hu X; Zhang Y; Liu D
    J Pharm Pharm Sci; 2020; 23():422-436. PubMed ID: 33137282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
    Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
    J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment.
    Stummer A; Ristl R; Kogler B; Muskovich M; Kossmeier M; Stulnig TM
    Wien Klin Wochenschr; 2023 Jul; 135(13-14):375-382. PubMed ID: 36808306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis.
    Farmakis I; Doundoulakis I; Pagiantza A; Zafeiropoulos S; Antza C; Karvounis H; Giannakoulas G
    J Cardiovasc Pharmacol; 2021 Mar; 77(3):397-407. PubMed ID: 33298738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.